Lipoprotein(a): a genetic marker for cardiovascular disease and target for emerging therapies. Issue 3 (27th March 2021)

• Record Type: Journal Article
• Authors: Cesaro, Arturo; Schiavo, Alessandra; Moscarella, Elisabetta; Coletta, Silvio; Conte, Matteo; Gragnano, Felice; Fimiani, Fabio; Monda, Emanuele; Caiazza, Martina; Limongelli, Giuseppe; D'Erasmo, Laura; Riccio, Carmine; Arca, Marcello; Calabrò, Paolo
• Is Part Of: Journal of cardiovascular medicine. Volume 22:Issue 3(2021)
• Page Start: 151
• Page End: 161
• Publication Date: 2021-03-27
• Subjects: atherosclerosis -- biomarker -- cardiovascular prevention -- lipoprotein(a) -- dyslipidemia; Cardiology -- Periodicals; Cardiovascular system -- Diseases -- Periodicals; Cardiology -- Periodicals; Cardiovascular Diseases -- Periodicals; 616.1005
• DOI: 10.2459/JCM.0000000000001077
• Languages: English
• ISSNs: 1558-2027

Abstract

Abstract : Lipoprotein(a) [Lp(a)] is an established cardiovascular risk factor, and growing evidence indicates its causal association with atherosclerotic disease because of the proatherogenic low-density lipoprotein (LDL)-like properties and the prothrombotic plasminogen-like activity of apolipoprotein(a) [apo(a)]. As genetics significantly influences its plasma concentration, Lp(a) is considered an inherited risk factor of atherosclerotic cardiovascular disease (ASCVD), especially in young individuals. Moreover, it has been suggested that elevated Lp(a) may significantly contribute to residual cardiovascular risk in patients with coronary artery disease and optimal LDL-C levels. Nonetheless, the fascinating hypothesis that lowering Lp(a) could reduce the risk of cardiovascular events – in primary or secondary prevention – still needs to be demonstrated by randomized clinical trials. To date, no specific Lp(a)-lowering agent has been approved for reducing the lipoprotein levels, and current lipid-lowering drugs have limited effects. In the future, emerging therapies targeting Lp(a) may offer the possibility to further investigate the relation between Lp(a) levels and cardiovascular outcomes in randomized controlled trials, ultimately leading to a new era in cardiovascular prevention. In this review, we aim to provide an updated overview of current evidence on Lp(a) as well as currently investigated therapeutic strategies that specifically address the reduction of the lipoprotein.